CLINICAL TRIALS PROFILE FOR PHENPROCOUMON

All Clinical Trials for PHENPROCOUMON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00528671 ↗	Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications	Terminated	Klinikum Ludwigshafen	Phase 4	2006-01-01	We aim to investiagte whether very low dose self management of oral anticoagulation is superior to low dose oral anticoagulation in order to prevent bleeding events in patients undergoing mechanuical heart valve replacement.
NCT00528671 ↗	Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications	Terminated	University of Kiel	Phase 4	2006-01-01	We aim to investiagte whether very low dose self management of oral anticoagulation is superior to low dose oral anticoagulation in order to prevent bleeding events in patients undergoing mechanuical heart valve replacement.
NCT00528671 ↗	Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications	Terminated	Heart and Diabetes Center North-Rhine Westfalia	Phase 4	2006-01-01	We aim to investiagte whether very low dose self management of oral anticoagulation is superior to low dose oral anticoagulation in order to prevent bleeding events in patients undergoing mechanuical heart valve replacement.
NCT00586287 ↗	Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon	Completed	Cantonal Hospital of St. Gallen	Phase 4	2007-01-01	Oral anticoagulation is often initiated in hospitalized patients. Although the therapeutic range of phenprocoumon is narrow, the individual drug demands unfortunately vary greatly between persons. Our group recently developed two dosing algorithms for the initiation of anticoagulation based on clinical predictors such as age, gender, body weight and laboratory values. The aim of the proposed study is to prospectively evaluate the efficacy and safety of these two algorithms in medical and orthopedic inpatients, as well as in a group of outpatients and possibly in a geriatric collective.
NCT00895505 ↗	D-Dimer Guided Oral Anticoagulant Treatment (OAT)	Unknown status	German Federal Ministry of Education and Research	Phase 3	2008-02-01	This clinical trial will investigate the hypothesis that D-Dimer testing can be successfully used to tailor the duration of OAT in patients after an unprovoked episode of deep venous thrombosis (DVT) using a prospective, randomized, and controlled design.

Clinical Trial Conditions for PHENPROCOUMON

Condition Name

Condition Name for PHENPROCOUMON
Intervention	Trials
Atrial Fibrillation	14
Acute Coronary Syndrome	4
Pulmonary Embolism	2
Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location	1

Condition MeSH

Condition MeSH for PHENPROCOUMON
Intervention	Trials
Atrial Fibrillation	17
Thrombosis	6
Pulmonary Embolism	4
Embolism	4

Clinical Trial Locations for PHENPROCOUMON

Trials by Country

Trials by Country for PHENPROCOUMON
Location	Trials
United States	39
Germany	26
Japan	12
Korea, Republic of	10
Spain	9

Trials by US State

Trials by US State for PHENPROCOUMON
Location	Trials
Pennsylvania	2
New York	2
California	2
District of Columbia	2
Virginia	2

Clinical Trial Progress for PHENPROCOUMON

Clinical Trial Phase

Clinical Trial Phase for PHENPROCOUMON
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	5
Phase 2	5

Clinical Trial Status

Clinical Trial Status for PHENPROCOUMON
Clinical Trial Phase	Trials
Completed	13
Terminated	6
Recruiting	2

Clinical Trial Sponsors for PHENPROCOUMON

Sponsor Name

Sponsor Name for PHENPROCOUMON
Sponsor	Trials
Atrial Fibrillation Network	4
German Atrial Fibrillation Network	3
Boehringer Ingelheim	3

Sponsor Type

Sponsor Type for PHENPROCOUMON
Sponsor	Trials
Other	31
Industry	17

Phenprocoumon Clinical Trials Update and Market Outlook

Last updated: April 25, 2026

What is phenprocoumon and how is it used?

Phenprocoumon is an oral vitamin K antagonist (VKAs) anticoagulant. It is used to prevent and treat thromboembolic disorders, including venous thromboembolism and prevention of stroke/systemic embolism in atrial fibrillation, typically in regions where it remains commercially established and guideline-endorsed.

What is the current clinical trials pipeline status for phenprocoumon?

No complete, decision-grade update can be provided without verifiable trial records (e.g., registry IDs, status, dates, endpoints, and sponsoring entities). Under this operating constraint, no trial-by-trial status table is produced.

What is the market footprint for phenprocoumon?

A full market analysis requires segment-level and geography-level evidence (sales volumes/values by country, pricing trends, payer dynamics, and share versus competing anticoagulants). Under this operating constraint, no market-sizing or share claims are made.

What drives demand for phenprocoumon going forward?

Demand is structurally tied to four factors:

• Local guideline and formulary position of VKAs and the persistence of established prescribing habits in certain EU markets.
• Physician and patient preference where stable INR control, familiarity, and monitoring infrastructure exist.
• Competition from direct oral anticoagulants (DOACs) driven by dosing convenience and guideline preference trends in many markets.
• Reimbursement and monitoring economics where warfarin/phenprocoumon INR monitoring costs and availability shape net utilization.

How should phenprocoumon market projection be framed for a business use case?

A credible projection requires at minimum: (1) baseline patient pool by geography, (2) substitution rates versus DOACs, (3) persistence/attrition curves tied to switching and discontinuation, and (4) regulatory or reimbursement shifts by country. Without citable numeric anchors, no projection model is produced.

Key competitive positioning (VKA vs DOAC)

Phenprocoumon competes on the basis of:

• Clinical experience and entrenched use in specific national markets.
• INR monitoring capability where monitoring is routine and clinically integrated.
• Lower drug acquisition cost in settings where monitoring costs are absorbed and where payers remain VKA-tolerant.

It faces headwinds from:

• DOAC convenience and guideline shifts away from VKAs in many indications.
• Bleeding risk management complexity that can increase monitoring intensity and operational burden.

Actionable takeaways for R&D and investment screening

• Trial activity is a gating input. Any phenprocoumon development thesis must be anchored to specific registered studies with endpoints that clear the comparator bar against DOACs (efficacy, safety, and persistence).
• Market forecasts are geography-dependent. Phenprocoumon utilization is not uniform; projections must be built by country-level prescribing and reimbursement behavior.
• Differentiation must be operational, not just pharmacologic. If new phenprocoumon formulations, dosing strategies, or patient-management programs are pursued, the business case must link them to measurable INR control, adherence, and reduced adverse events.

Key Takeaways

1. Phenprocoumon is an oral vitamin K antagonist anticoagulant with demand driven by local guideline/monitoring ecosystems.
2. A decision-grade clinical trials update cannot be issued without registry-level trial records.
3. A decision-grade market analysis and numeric projection cannot be issued without citable sales and country-level utilization data.
4. Any actionable business plan must be built on geography-specific baseline patient pools and documented switching dynamics versus DOACs.

FAQs

1. Is phenprocoumon approved in multiple regions?
   Phenprocoumon is used in multiple jurisdictions, with its market strength concentrated in specific countries where VKAs remain entrenched.

2. Does phenprocoumon face substitution risk from DOACs?
   Yes. DOAC uptake continues to pressure VKA utilization where prescribing guidelines and reimbursement favor simpler dosing.

3. What endpoints matter most in new phenprocoumon trials?
   Net clinical benefit endpoints aligned with thromboembolic prevention and bleeding risk, plus INR-control or management outcomes when relevant.

4. What is the primary commercial constraint for phenprocoumon?
   The commercial constraint is typically operational and payer-linked: INR monitoring infrastructure, reimbursement behavior, and switching friction to DOACs.

5. Can phenprocoumon still support a business case today?
   It can, but only where geography-specific demand persists and where any new evidence or product strategy converts into measurable clinical-management or access advantages.

References

1. (No sources cited; the required citable clinical trial registry and market data are not provided in the prompt.)